Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DYADIC INTERNATIONAL, INC.

(DYAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

07/27/2021 | 08:20am EDT

Dyadic International, Inc. announced it signed a COVID-19 vaccine technology transfer and licensing agreement (the “Rubic Agreement”) with the Rubic Consortium (“Rubic”), a South African-based company whose mission is to develop a South African-based solution for the discovery, development, evaluation and manufacture of high-quality, cost-effective vaccines for distribution primarily to the African markets. Some of the highlights of the Rubic Agreement are as follows: Rubic will be licensed to utilize the C1 Platform for the research, development, regulatory approval, manufacture, launch, marketing, and commercialization of a COVID-19 vaccine(s) that may be manufactured in South Africa and sold in multiple countries on the African continent. Rubic will be responsible for presenting the proposed design and funding of a Phase II clinical trial within a specified timeframe of the executed technology transfer and licensing agreement. Rubic, subject to certain terms and conditions, may utilize the C1 platform to conduct research and development, conduct pre-clinical studies and clinical studies and commercialize COVID-19 and other vaccines. Rubic will initiate a detailed review of locations in South Africa suitable for use as a cGMP Source for CoV-2 bulk materials at a facility owned or controlled by Rubic. Dyadic will facilitate technology transfer of the C1 Platform to Rubic through the completion of clinical trials. Other than as provided by the Rubic Agreement, Dyadic will have the exclusive license and right to make, have made, use, sell, offer to sell, market, and commercialize any COVID-19 commercial product arising from joint development with Rubic. The agreement provides Rubic with the ability to conduct research and development activities with multiple other C1 produced vaccines in addition to DYAI-100. Dyadic will maintain and own all background and foreground intellectual property rights relating to the C1 platform, derived from any and all research and development as a result of the project.


© S&P Capital IQ 2021
All news about DYADIC INTERNATIONAL, INC.
09/20DYADIC INTERNATIONAL, INC.(NASDAQCM : DYAI) dropped from S&P Global BMI Index
CI
09/16DYADIC INTERNATIONAL : BPI East September 2021
PU
09/11DYADIC INTERNATIONAL : H.C. Wainwright 23rd Annual Global Investment Conference
PU
09/10DYADIC INTERNATIONAL : to Present at H.C. Wainwright 23rd Annual Global Investment Confere..
AQ
08/19SORRENTO THERAPEUTICS : vaccine shows promise against coronavirus, variants in animal stud..
RE
08/19SORRENTO THERAPEUTICS : Dyadic COVID-19 Vaccine Candidate Elicits "Strong" Immune Response..
MT
08/17DYADIC INTERNATIONAL : Insider Sale Slows Buying Trend of Last Quarter at Dyadic Internati..
MT
08/16INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Dyadic International
MT
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlights Recent..
PU
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlights Recent..
PU
More news
Financials (USD)
Sales 2021 3,00 M - -
Net income 2021 -11,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,3x
Yield 2021 -
Capitalization 161 M 161 M -
Capi. / Sales 2021 53,6x
Capi. / Sales 2022 48,8x
Nbr of Employees 6
Free-Float 49,2%
Chart DYADIC INTERNATIONAL, INC.
Duration : Period :
Dyadic International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYADIC INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 5,73 $
Average target price 10,00 $
Spread / Average Target 74,5%
EPS Revisions
Managers and Directors
Mark A. Emalfarb President, Chief Executive Officer & Director
Ping W. Rawson Chief Financial Officer
Michael P. Tarnok Chairman
Ronen Tchelet Vice President-Research & Business Development
Seth J. Herbst Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DYADIC INTERNATIONAL, INC.5.39%159
MODERNA, INC.311.74%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.01%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-7.88%30 241